肝癌肝动脉超选择栓塞化疗的临床应用.docVIP

肝癌肝动脉超选择栓塞化疗的临床应用.doc

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
肝癌肝动脉超选择栓塞化疗的临床应用 The Clinical Application of Ssuperselective Embolism Chemotherapy Transhepatic Artery for Hepatic Carcimoma 何泽清 刘国庆 汪明全 刘兴华 罗江平 He Zeqing, Liu Guoqing, Wang Mingquan, Liu Xinghua, Luo jiangping 重庆三峡中心医院CT、MR科 (中国 404000) Department of CT/MRI, Chongqing Three Gorges Central Hospital (China 404000) 中图分类号:R735.7 文献标识码:A 文章编号:1818-0086(2011)05 摘要:目的 探讨经肝动脉超选择栓塞化疗在肝癌治疗中的临床应用价值。方法 回顾性分析介入法冶疗的639例肝癌患者,对其中312例采用超选择肝动脉栓塞化疗的病例分析造影征像,碘油沉积情况及冶疗效果。结果 312例肝癌患者肝动脉造影显示,289例肝癌血管丰富,肿癌染色明显,边缘可见,其中巨块型158例,结节型112例,弥漫型42例。术后一月CT复查,117例碘油致密填塞(其中32例肿块缩小,85例肿块无变化),195例未致密填塞(52例肿块增大,143例肿块大小无变化)。临床随访1年、2年、3年以上生成率分别为84.93%(265/312),69.22%(216/312),53.84%(168/312)。结论 肝癌肝动脉超选择栓塞化疗,临床疗效显著,应作为一项重要的非手术治疗手段。 关键词:肝癌;超选择栓塞化疗;治疗 Abstact:Objective To investigate the clinical value of trans-arterial chemoembolization (TACE) for hepatic carcinoma. Methods Retrospectively analyzed the data of 639 patients with hepatic carcinoma received interventional therapy, angiographic signs, lipiodol-deposited features and treatment effectiveness in 312 cases received TACE were analyzed. Results Among 312 cases received hepatic arteriography, 289 cases had abundant blood vessels, stained obviously, had visible border. In 289 cases, the lesions were classified into three types, giant mass type (158), nodular type (112), and diffuse type (42). CT were performed one month later post-TACE, lipiodol fulfilled completely in 117cases (among them, the mass decreased in 32 cases, 85 cased had no change), lipiodol deposited partly in 195 cases (among them, the mass enlarged in 52 cases, 143 cased had no obviously change in size ), respectively. Clinical follow-up 1 year, 2 years, and more than 3 years after TACE, the survival rate were 84.93% (265/312), 69.22% (216/312), 53.84% (168/312), respectively. Conclusion TACE for hepatic carcinoma had evident treatment effectiveness, and should become one important non-surgical operation therapeutic means. Key words:Hepatic carcinoma;Superselective e

文档评论(0)

天马行空 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档